Abstract: An embodiment relaxation seat for a vehicle includes a seat cushion lower frame configured to be mounted on a seat rail, a seat cushion upper frame connected to the seat cushion lower frame in a tilting-enabled manner, a seat back frame connected to the seat cushion upper frame, a locking device mounted at a predetermined position on the seat cushion upper frame, a front link hinge-connecting between the seat cushion upper frame and a front end portion of the seat cushion lower frame, a rear link hinge-connecting between the seat cushion upper frame and a rear end portion of the seat cushion lower frame, and a support bar connecting between the locking device and the front link in a manner that is movable backward and forward and configured to support the front link for rotation or fixation thereof.

Abstract: This application relates to a noise signal generating apparatus. In one aspect, the apparatus includes a bandwidth expansion unit configured to generate a noise signal having a second bandwidth by expanding a noise source signal having a first bandwidth to the second bandwidth that is greater than the first bandwidth. The apparatus may also include a randomization unit configured to perform randomization and output the generated noise signal having the second bandwidth.

Abstract: Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.

Abstract: This disclosure provides a novel lyophilized formulation that incorporates a surfactant solution to stabilize the Sabin inactivated polio vaccine and demonstrate the vaccine efficacy in an in vivo challenge model. Furthermore, SE-HPLC analysis of D-antigen content in in inactivated polio vaccine can be used to provide a method for high throughput evaluation of inactivated poliovirus stability.

Abstract: Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.

Abstract: Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.

Abstract: The present invention provides improved formulations for lysosomal enzymes useful for enzyme replacement therapy. Among other things, the present invention provides formulations that preserve or enhance the stability and/or efficacy of a lysosomal enzyme such as acid alpha-glucosidase.

Abstract: The present invention provides improved formulations for lysosomal enzymes useful for enzyme replacement therapy. Among other things, the present invention provides formulations that preserve or enhance the stability and/or efficacy of a lysosomal enzyme such as acid alpha-glucosidase.

Abstract: A stabilized pharmaceutical composition in the form of a lyophilized product to be later reconstituted to generate an aqueous drug product is described herein. The therapeutically active ingredient in the form of a peptide of sequence TDLQERGDNDISPFSGDGQPFKD is stabilized with a buffer, carbohydrate stabilizer, a nonionic bulking agent and a surfactant to facilitate reconstitution. The preferred preparation contains a peptide of the sequence TDLQERGDNDISPFSGDGQPFKD, histidine buffer, mannitol or glycine, sucrose and/or Polysorbate 20. This combination of excipients has demonstrated exceptional stability as a lyophilized product when stored at the elevated temperature of 40° C. for at least 6 months and for at least 3 Months at 50° C. The lyophilized mixture thus formed is reconstituted to a high peptide concentration without apparent loss of stability of the peptide.

Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.

Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.

Abstract: A stabilized pharmaceutical composition in the form of a lyophilized product to be later reconstituted to generate an aqueous drug product is described herein. The therapeutically active ingredient in the form of a peptide of sequence TDLQERGDNDISPFSGDGQPFKD is stabilized with a buffer, carbohydrate stabilizer, a nonionic bulking agent and a surfactant to facilitate reconstitution. The preferred preparation contains a peptide of the sequence TDLQERGDNDISPFSGDGQPFKD, histidine buffer, mannitol or glycine, sucrose and/or Polysorbate 20. This combination of excipients has demonstrated exceptional stability as a lyophilized product when stored at the elevated temperature of 40° C. for at least 6 months and for at least 3 Months at 50° C. The lyophilized mixture thus formed is reconstituted to a high peptide concentration without apparent loss of stability of the peptide.

Abstract: Stabilized solid and liquid pharmaceutical formulations comprising a GHRH molecules as active ingredient, and more particularly GHRH analogs including [trans-3-hexenoyl]hGHRH (1-44) amide, are disclosed. The formulation comprises an anionic surfactant and a non-reducing sugar, and has a pH of about 4.0 to about 7.5. Also disclosed is the use of the formulation for the treatment of various conditions, methods of preparing the formulation, as well as kits containing it.

Abstract: A container closure delivery system that is suitable for lyophilized pharmaceutical injectable powder products is disclosed. The system comprises storage stable powder formulations and a container closure assembly design wherein the formulation can be filled and lyophilized with a standard fill finish equipment, and the formulations and lyophilization processes are optimized to produce a powder that readily dissolves upon contact with a diluent, thereby facilitating the direct injection of the lyophilized product without the need for a separate reconstitution/mixing/priming step.

Abstract: A container closure delivery system that is suitable for lyophilized pharmaceutical injectable powder products is disclosed. The system comprises storage stable powder formulations and a container closure assembly design wherein the formulation can be filled and lyophilized with a standard fill finish equipment, and the formulations and lyophilization processes are optimized to produce a powder that readily dissolves upon contact with a diluent, thereby facilitating the direct injection of the lyophilized product without the need for a separate reconstitution/mixing/priming step. Importantly, the container closure assembly also provides for modularity of dosing, the ability to dose multiple products in a single dose, intranasal delivery, and multi-dosing.

Abstract: The present invention relates to a container closure delivery system that is suitable for lyophilized pharmaceutical injectable powder products. The system comprises storage stable powder formulations and a container closure assembly design wherein the formulation can be filled and lyophilized with a standard fill finish equipment, and the formulations and lyophilization processes are optimized to produce a powder that readily dissolves upon contact with a diluent, thereby facilitating the direct injection of the lyophilized product without the need for a separate reconstitution/mixing/priming step.

Abstract: A computer having a speaker outputting a sound, the computer including: a sound signal output unit outputting a speaker sound signal to the speaker; a speaker output control unit controlling whether the sound signal output unit to output the speaker sound signal; and an alarm control unit controlling the speaker output control unit so that the sound signal output unit outputs the speaker sound signal when a predetermined alarm condition is detected, and the sound signal output unit so that the speaker generates a preset alarm sound to correspond to the alarm condition.

Abstract: A computing device allows selective output of audio signals within a frequency band. The computing device has a main system having an audio signal generator generating audio signals, a main audio outputting unit attached to the main system and outputting the generated audio signals, an auxiliary system connected to the main system and receiving the audio signals generated by the audio signal generating unit, and an auxiliary audio outputting unit attached to the auxiliary system and outputting the audio signals received in the auxiliary system A switching unit controls the audio signals to pass through a plurality of selectable filters filtering the audio signals within respective frequency bands and to supply the selected filtered audio signals to the main audio outputting unit, and to the auxiliary audio outputting unit, depending upon whether the auxiliary system is connected to the main system.

Abstract: A computing device allows selective output of audio signals within a frequency band. The computing device has a main system having an audio signal generator generating audio signals, a main audio outputting unit attached to the main system and outputting the generated audio signals, an auxiliary system connected to the main system and receiving the audio signals generated by the audio signal generating unit, and an auxiliary audio outputting unit attached to the auxiliary system and outputting the audio signals received in the auxiliary system A switching unit controls the audio signals to pass through a plurality of selectable filters filtering the audio signals within respective frequency bands and to supply the selected filtered audio signals to the main audio outputting unit, and to the auxiliary audio outputting unit, depending upon whether the auxiliary system is connected to the main system.

Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.